ORGS (Orgenesis) Cyclically Adjusted PS Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGS Orgenesis Inc ORGS
12 GF Score
Price $0.10
View Full Analysis

What is Orgenesis Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis  (OTCPK:ORGS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Orgenesis Cyclically Adjusted PS Ratio Related Terms


Orgenesis Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Orgenesis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Cyclically Adjusted PS Ratio Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.13 3.23 1.93 0.54 0.00

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.89 0.67 0.51 0.00

ORGS vs ENDV, GBLX, OMGAQ: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted PS Ratio falls into.


ORGS
12GF Score
Orgenesis Inc ORGS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Orgenesis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Orgenesis's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.06/315.6050*315.6050
=0.060

Current CPI (Dec. 2024) = 315.6050.

Orgenesis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201502 0.000 234.722 0.000
201505 1.568 237.805 2.081
201508 1.994 238.316 2.641
201511 2.606 237.336 3.465
201602 1.769 237.111 2.355
201605 1.262 240.229 1.658
201608 1.995 240.849 2.614
201611 2.752 241.353 3.599
201702 1.994 243.603 2.583
201705 2.401 244.733 3.096
201708 2.466 245.519 3.170
201711 3.263 246.669 4.175
201802 2.445 248.991 3.099
201805 3.034 251.588 3.806
201808 4.338 252.146 5.430
201811 3.825 252.038 4.790
201903 4.689 254.202 5.822
201906 0.707 256.143 0.871
201909 5.690 256.759 6.994
201912 -12.628 256.974 -15.509
202003 1.056 258.115 1.291
202006 0.813 257.797 0.995
202009 0.783 260.280 0.949
202012 0.962 260.474 1.166
202103 3.881 264.877 4.624
202106 4.327 271.696 5.026
202109 3.573 274.310 4.111
202112 2.841 278.802 3.216
202203 2.932 287.504 3.219
202206 2.901 296.311 3.090
202209 3.145 296.808 3.344
202212 5.332 296.797 5.670
202303 0.054 301.836 0.056
202306 0.040 305.109 0.041
202309 0.037 307.789 0.038
202312 0.055 306.746 0.057
202403 0.042 312.332 0.042
202406 0.063 314.175 0.063
202409 0.074 315.301 0.074
202412 0.060 315.605 0.060

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for ORGS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price